Talk:CD19
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
| ||||||||||||||
Untitled
[edit]DFAS —Preceding unsigned comment added by 128.192.23.183 (talk) 17:52, 11 August 2008 (UTC)
I think something should be mentioned about the use of CD19 as a B cell neoplasm target (most recently as a target for CAR-modified T cells in CLL cf http://www.ncbi.nlm.nih.gov/pubmed/21830940 ) Ulalume (talk) 18:14, 3 November 2011 (UTC)
Use as immunoconjugate target
[edit]eg in B43-genistein, an anti-CD19 antibody linked to genistein eg for leukemia. : Chen; et al. (1999). "Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies". {{cite journal}}: Cite journal requires |journal= (help); Explicit use of et al. in: |author= (help)
- Rod57 (talk) 00:03, 10 June 2013 (UTC)